Stable high concentration sodium chloride formulations containing pd-1 antibody and methods of use thereof

Patent metadata

Field	Value
Publication number	US-2025084168-A1
Application number	US-202418910935-A
Country	US
Kind code	A1
Filing date	Oct 9, 2024
Priority date	Apr 14, 2022
Publication date	Mar 13, 2025
Grant date	—

Abstract

The present invention relates generally to the field of pharmaceutical formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. The formulations may further contain a histidine buffer, an inorganic salt, a sugar polyol, and a non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit low viscosity and a substantial degree of antibody stability after being subjected to thermal and other physical stress. Also provided are methods of making and methods of using such antibody formulations.

First claim

1 . A low viscosity pharmaceutical formulation comprising:
about 10 mg/mL to about 200 mg/mL of an anti programmed death receptor 1 (PD-1) antibody, or antigen binding fragment thereof; a formulation buffer providing a pH of about 5.0 to about 7.0; a sugar polyol; a viscosity reducer; and a non-ionic surfactant, wherein the pharmaceutical formulation has a viscosity of no more than 30 cP, and an osmolarity from about 200 mOsmol/kg to about 400 mOsmol/kg.

2 . The formulation of claim 1 , wherein the PD-1 antibody or antigen binding fragment thereof, comprises a heavy chain variable region (a) a HCDR1 (Heavy Chain Complementarity Determining Region 1) of SEQ ID NO: 1, (b) a HCDR2 of SEQ ID NO:2, (c) a HCDR3 of SEQ ID NO:3 and a light chain variable region that comprises: (d) a LCDR1 (Light Chain Complementarity Determining Region 1) of SEQ ID NO:4, (e) a LCDR2 of SEQ ID NO:5, and (f) a LCDR3 of SEQ ID NO:6.

3 . The formulation of claim 2 , wherein the formulation buffer is:
(a) selected from the group consisting of histidine, acetate, citrate, succinate, phosphate, mixture of histidine and acetic acid, or mixture of histidine and citric acid; or (b) histidine.

4 . (canceled)

5 . The formulation of claim 3 , wherein the concentration of buffer is 15 mM to 25 mM.

6 . The formulation of claim 5 , wherein;
(a) the formulation comprises 20 mM histidine buffer; (b) the pH is 5.5-6.0; or (c) a combination thereof.

7 . (canceled)

8 . The formulation of claim 1 , wherein the sugar polyol is:
(a) selected from the group consisting of trehalose, sucrose, sorbitol, mannitol, maltose, dextran, or (2-hydroxypropyl)-β-cyclodextrin, or (b) trehalose.

9 . (canceled)

10 . The formulation of claim 8 , wherein the trehalose concentration is:
(a) from 70 mM to 240 mM; (b) from 80 mM to 160 mM; (c) from 70 mM to 100 mM; or (d) 80 mM.

11 . (canceled)

12 . (canceled)

13 . (canceled)

14 . The formulation of claim 1 , wherein the viscosity reducer is an inorganic salt selected from the group consisting of sodium chloride, magnesium chloride, calcium chloride, sodium acetate, sodium sulfate, ammonium chloride or ammonium sulfate.

15 . The formulation of claim 14 , wherein the inorganic salt is sodium chloride at a concentration of 50 mM to 150 mM,

16 . The formulation of claim 15 , wherein the sodium chloride is at a concentration of:
(a) 50 mM to 100 mM, or (b) 70 mM.

17 . (canceled)

18 . The formulation of claim 1 , wherein the non-ionic surfactant is selected from the group consisting of polysorbate 20, polysorbate 80 or poloxamer 188.

19 . The formulation of claim 18 , wherein the concentration of polysorbate 20 is:
(a) from 0.02% to 0.08%, or (b) 0.08%.

20 . (canceled)

21 . The formulation of claim 1 , wherein the formulation comprises:
(a) 20 mM Histidine-Histidine HCl, 100 mM NaCl, 70 mM trehalose and 0.08% polysorbate 20, with a pH of pH6.0; (b) 20 mM Histidine-Histidine HCl, 50 mM NaCl, 100 mM trehalose and 0.02% polysorbate 20, with a pH of pH6.0; or (c) 20 mM Histidine-Histidine HCl, 70 mM NaCl, 80 mM trehalose and 0.08% polysorbate 20 with a pH of pH6.0.

22 . (canceled)

23 . (canceled)

24 . The formulation of claim 1 , wherein the concentration of the anti-human PD-1 antibody, or antigen binding fragment thereof is from about 100 mg/mL to 200 mg/mL.

25 . A method of making an antibody formulation, the method comprising:
(a) adding trehalose and sodium chloride to the antibody to achieve an antibody formulation having a concentration of trehalose no less than 50 mM and a concentration of sodium chloride no less than 25 mM, wherein the antibody comprises a heavy chain variable region (a) a HCDR1 (Heavy Chain Complementarity Determining Region 1) of SEQ ID NO: 1, (b) a HCDR2 of SEQ ID NO:2, (c) a HCDR3 of SEQ ID NO:3 and a light chain variable region that comprises: (d) a LCDR1 (Light Chain Complementarity Determining Region 1) of SEQ ID NO:4, (e) a LCDR2 of SEQ ID NO:5, and (f) a LCDR3 of SEQ ID NO:6; (b) concentrating the antibody formulation of (a) from 150-200 mg/mL; and (c) adding polysorbate 20 to the antibody formulation of (b) to obtain an antibody formulation having a concentration of polysorbate 20 of no less than 0.01 mg/mL, wherein the antibody formulation of (c) is in an aqueous solution and has a viscosity of no more than 30 cP at 25° C., and wherein the antibody formulation of (c) is stable upon agitation, freeze-thaw and thermal stress.

26 . A method for treating cancer in a human patient in need thereof comprising subcutaneous administration of an effective amount of an anti-human PD-1 antibody formulation of claim 1 .

27 . The method of claim 26 , wherein the anti-human PD-1 antibody formulation is subcutaneously administered at a dose of about 100 mg to about 1000 mg.

28 . The method of claim 27 , wherein the anti-human PD-1 antibody formulation is subcutaneously administered:
(a) at a dose of 200 mg; (b) at a dose of 300 mg; (c) at a dose of 400 mg; (d) at a dose of 500 mg; (e) once a week; (f) once every 2 weeks; (g) once every 3 weeks; or (h) any combination thereof.

29 . (canceled)

30 . (canceled)

31 . (canceled)

32 . (canceled)

33 . (canceled)

34 . (canceled)

35 . The method of claim 26 , wherein the cancer is lung cancer, small-cell lung cancer, non-small cell lung cancer, adrenal cancer, liver cancer, stomach cancer, cervical cancer, melanoma, renal cancer, breast cancer, colorectal cancer, leukemia, bladder cancer, bone cancer, brain cancer, an endometrial cancer, head and neck cancer, lymphoma, ovarian cancer, skin cancer, thyroid tumor, or esophageal cancer.

36 . The method of claim 26 , wherein the human patient is administered at least one other therapeutic agent.

37 . The method of claim 36 , wherein the at least one other therapeutic agent is zanubrutinib, pamiparib, an anti-CTLA4 antibody, an anti-4-1BB antibody, an anti-OX40 antibody, an anti-TIGIT antibody, an anti-TIM-3 antibody, a second PD-1 antibody, a CD40 agonist, a TLR agonist, a CAR-T cell, or a chemotherapeutic agent.

Assignees

• Beigene Switzerland Gmbh

Inventors

• Wu Jun
• Jin Xiaoqing
• Ji Yu
• Gu Sufang
• Shen Jian
• Qiu Bo

Classifications

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• A61K2039/55511

  Organic adjuvants · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K16/2818 Primary

  against CD28 or CD152 · CPC title